UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G Under the Securities Exchange Act of 1934

IMPRIMIS PHARMACEUTICALS, INC.

(Name of Issuer)

Common Stock, \$0.001 par value

(Title of Class of Securities)

45323A 102

(CUSIP Number)

July 12, 2012

(Date of Event Which Requires Filing of this Statement)

filed:	ne appropriate box to designate the rule pursuant to which this Schedule is
[☐ Rule 13d-1(b)
[x Rule 13d-1(c)
[☐ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 45323A 102		13G	Page 2 of 5 Pages		
1. Names of Reporting Persons.					
Donald Miloni					
2. Check the Appropriate Box if a Member of a Group (see instructions)					
			(a)		
3. SEC Use Only			(b) [
4. Citizenship or Place of	of Organization				
	or organization				
U.S.A					
	5. Sole Voting	Power			
	4,469,289 ¹				
	6. Shared Voti	ng Power			
Number of Shares Beneficially					
Owned by	1,748,277 ² 7. Sole Dispos	itiya Dayyar			
Each Reporting Person With:	7. Sole Dispos	luve rowei			
reison with.	4,469,289 ¹				
	8. Shared Disp	ositive Power			
	1,748,277 ²				
9. Aggregate Amount Beneficially Owned by Each Reporting Person					
	· · · · ·				
6,217,566 ³					
10. Check if the Aggreg	gate Amount in Ro	ow (9) Excludes Certain Shares (see instruct	ions)		
11. Percent of Class Re	presented by Amo	ount in Row 9	Ц		
18.1%4					
12. Type of Reporting P	Person (see instruc	ctions)			
IN					

^{1.} Includes (i) 4,392,879 shares of the Issuer's common stock held in the name of the person filing this Schedule 13G, and (ii) 76,410 shares of the Issuer's common stock underlying warrants issued in the name of the person filing this Schedule 13G and exercisable within 60 days after the date of filing this Schedule 13G.

^{2.} Includes (i) 126,582 shares of the Issuer's common stock and 31,646 shares of the Issuer's common stock underlying warrants exercisable within 60 days after the date of filing this Schedule 13G, each held in the name of the spouse of the person filing this Schedule 13G, (ii) 759,494, shares of the Issuer's common stock and 189,874 shares of the Issuer's common stock underlying warrants exercisable within 60 days after the date of filing this Schedule 13G, each held in the name of 1425 Greenwood Lane, LLC, of which the person filing this Schedule 13G is a managing member, and (iii) 513,829 shares of the Issuer's common stock and 126,852 shares of the Issuer's common stock underlying warrants exercisable within 60 days after the date of filing this Schedule 13G, each held in the name of RCHER Financial, LLC, of which the person filing this Schedule 13G is a managing member.

^{3.} Consists of the securities set forth in footnotes (1) and (2) above. The person filing this Schedule 13G disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

^{4.} The percentage was calculated based on 34,284,409 shares of the Issuer's common stock, as follows: (i) 33,859,627 shares of the Issuer's common stock outstanding as of August 31, 2012, and (ii) 424,782 shares of the Issuer's common stock underlying warrants issued in the name of the person filing this Schedule 13G and exercisable within 60 days after the date of filing this Schedule 13G.

Item 1(a). Name of Issuer:

Imprimis Pharmaceuticals, Inc.

Item 1(b). Address of Issuer's Principal Executive Offices:

437 S. Highway 101, Suite 209 Solana Beach, CA 92075

Item 2(a). Name of Person Filing:

Donald Miloni

Item 2(b) Address of Principal Business Office, or if None, Residence:

C/O Imprimis Pharmaceuticals, Inc. 437 S. Highway 101, Suite 209 Solana Beach, CA 92075

Item 2(c). Citizenship:

U.S.A.

Item 2(d). Title of Class of Securities:

Common Stock, par value \$0.001

Item 2(e). CUSIP Number:

45323A 102

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:

6,217,566*

(b) Percent of class:

18.1%

- (c) Number of shares as to which such person has:
 - (i) Sole power to vote or to direct the vote

4,469,289* (includes 4,392,879 shares of the Issuer's common stock held in the name of the person filing this Schedule 13G, and 76,410 shares of the Issuer's common stock underlying warrants issued in the name of the person filing this Schedule 13G and exercisable within 60 days after the date of filing this Schedule 13G).

(ii) Shared power to vote or to direct the vote

1,748,277*(includes (i) 126,582 shares of the Issuer's common stock and 31,646 shares of the Issuer's common stock underlying warrants exercisable within 60 days after the date of filing this Schedule 13G, each held in the name of the spouse of the person filing this Schedule 13G, (ii) 759,494, shares of the Issuer's common stock and 189,874 shares of the Issuer's common stock underlying warrants exercisable within 60 days after the date of filing this Schedule 13G, each held in the name of 1425 Greenwood Lane, LLC, of which the person filing this Schedule 13G is a managing member, and (iii) 513,829 shares of the Issuer's common stock and 126,852 shares of the Issuer's common stock underlying warrants exercisable within 60 days after the date of filing this Schedule 13G, each held in the name of RCHER Financial, LLC, of which the person filing this Schedule 13G is a managing member).

(iii) Sole power to dispose or to direct the disposition of

4,469,289* (includes 4,392,879 shares of the Issuer's common stock held in the name of the person filing this Schedule 13G, and 76,410 shares of the Issuer's common stock underlying warrants issued in the name of the person filing this Schedule 13G and exercisable within 60 days after the date of filing this Schedule 13G).

(iv) Shared power to dispose or to direct the disposition of

1,748,277*(includes (i) 126,582 shares of the Issuer's common stock and 31,646 shares of the Issuer's common stock underlying warrants exercisable within 60 days after the date of filing this Schedule 13G, each held in the name of the spouse of the person filing this Schedule 13G, (ii) 759,494, shares of the Issuer's common stock and 189,874 shares of the Issuer's common stock underlying warrants exercisable within 60 days after the date of filing this Schedule 13G, each held in the name of 1425 Greenwood Lane, LLC, of which the person filing this Schedule 13G is a managing member, and (iii) 513,829 shares of the Issuer's common stock and 126,852 shares of the Issuer's common stock underlying warrants exercisable within 60 days after the date of filing this Schedule 13G, each held in the name of RCHER Financial, LLC, of which the person filing this Schedule 13G is a managing member).

* The person filing this Schedule 13G disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Item 5. Ownership of Five Percent or Less of a Class.

Not Applicable.

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

Not Applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

Not Applicable.

Item 9. Notice of Dissolution of the Group.

Not Applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: September 6, 2012 DONALD MILONI

/s/ Donald Miloni

By: Donald Miloni, an individual